Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

NCT03099161 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped The data did not support study endpoints

Conditions

Neoplasm

Interventions

DRUG: preladenant
BIOLOGICAL: pembrolizumab

Sponsor

Merck Sharp & Dohme LLC